Please provide your email address to receive an email when new articles are posted on . An analysis of registry data from the United Network for Organ Sharing suggests that human leukocyte antigen ...
The aim of this study was to analyse the impact of HLA and non-HLA donor factors on transplant outcomes and to identify those factors important in donor selection. The final study population includes ...
Only 30% of patients in need of allo-HSCT will have a suitable human leukocyte antigen (HLA)-matched family member, and in the remainder an unrelated donor (UD) may be sought. 12 Although studies on ...
Please provide your email address to receive an email when new articles are posted on . For years, hematopoietic stem cell transplantation physicians have viewed a matched unrelated donor as the gold ...
HLA testing has been a staple in transplantation since the recognition that antibodies, directed against lymphocytes, were associated with allograft failure. This seminal finding led to the discovery ...
Evaluation of previous HLA typing for the Fred Hutchinson Cancer Center Clinical Coordinator Office prior to consult appointments (includes review of CIL and outside lab typing). Review and advice on ...
Analyses of two large stem-cell transplant registries yielded conflicting results about the effect of post-transplant cyclophosphamide (PTCy) for graft-versus-host disease (GVHD) prophylaxis on the ...
Post-Transplant Cyclophosphamide–Based Graft-Versus-Host Disease Prophylaxis Attenuates Disparity in Outcomes Between Use of Matched or Mismatched Unrelated Donors The study included 17,292 unrelated ...
To the Editor: Petersdorf et al. (Dec. 20 issue) 1 suggest that for patients with chronic myelogenous leukemia for whom a donor with an HLA class I mismatch cannot be avoided, “the preferred . . .
"Histo" means "tissue." Histocompatibility is defined as a measure of how well 2 tissues "get along with one another" when they find themselves in a confined space. The major physiologic barrier in ...
The Journal of Clinical Oncology podcast, hosted by Dr. Davide Soldato, presents analyses and discussions centered on the latest findings published in ASCO’s esteemed Journal of Clinical Oncology.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results